Acadia Pharmaceuticals rockets higher after it announces it has ended a phase 3 trial of its dementia-related psychosis treatment, pimavanserin, on better-than-expected results.
We're focused on Progenics Pharmaceuticals and Aerie Pharmaceuticals.
Lilly acquired the drug as part of its $8 billion acquisition of Loxo Oncology.
Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.
Both stocks have seen some recent insider buying.
Rova-T failed to show a survival benefit for patients when compared with a placebo.
They're the kind of names, along with a big dollop of cash in my portfolio, I plan to wait out the 'trade wars'.
The company will be the exclusive U.S. distributor of fungal disease medication Posaconazole delayed-release tablets.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.